Drive for 75: Week 20 Resources

Regulation | July 16, 2021 | by Jill Schumann

LeadingAge Coronavirus Update Calls feature brief segments called “Drive for 75” to promote the successful vaccination of at least 75% of our aging services providers’ workforce, and as needed, residents, by June 30. We will cover developments in the news, research, and innovative practices that support our members in attaining high vaccination rates.

This Week’s Highlights:

Volume Fifty: Air Date 7.12.21. “COVID-19 Vaccine and People with Disabilities”

The IMPACT WV project at the WVU Center for Excellence in Disabilities (WVU CED) is launching a new public health initiative, COVID-19 Vaccine Access and Confidence for People with Disabilities. The goal is to vaccinate all eligible people with disabilities by the anniversary of the Americans with Disabilities Act (ADA) on July 26th. The focus is on family conversations and Network centers will share information on the safety and efficacy of the COVID-19 vaccine in community meetings, newsletters, social media campaigns, short videos, and other local outreach efforts.

“This initiative builds upon IMPACT WV work, a two-generational way of thinking by providing key information about the COVID-19 vaccine for families to use when shaping their views of the vaccine for their health and future. “Providing the tools and resources to support those family conversations around health and vaccines will get us one step closer to our #VaccinateByADA goal and a healthier future.”

COVID-19 Vaccine Access and Confidence for People with Disabilities is made possible through a cooperative agreement with the Centers for Disease Control and Prevention (CDC). Learn more at: http://www.cedwvu.org and http:// https://wvimpact.org.

Volume Fifty One: Air Date 7.14.21. “Updates”

The first update is about the Johnson and Johnson vaccine. The J & J single-shot COVID-19 vaccine prompts a “strong neutralizing antibody response” that lasts at least eight months, according to the company. Studies of eight months of data show that the vaccine generates “persistent activity” against the Delta variant and other prevalent variants. The antibody response grows stronger over time according to J & J.

You may also have heard that this week the FDA has updated the label on the J & J vaccine to warn of the possible increased risk of a rare neurological complication known as Guillain-Barré syndrome. While the FDA said it had not established the vaccine could cause the syndrome, it noted an increase in reports of the sometimes paralyzing condition. The advice, however, continues to be that COVID risks far outweigh vaccine risks.

The second item is an update on the question of whether the lotteries that were begun to encourage vaccination have succeeded it their goals.

According to a study from the Boston University School of Medicine the answer is “No”. They looked at the state of Ohio’s “Vax-a-Million” lottery-based incentive system and concluded that the lottery did not increase the vaccination rate, contrary to early media reports.

Using data from the U.S. Centers of Disease Control to evaluate trends in vaccination rates among adults 18 and older, the researchers compared vaccination rates before and after the Ohio lottery versus other states in the U.S. that did not yet have vaccine incentive lottery programs. Vaccination rates in other states served as a “control” for vaccination trends measured in Ohio, allowing the researchers to account for factors besides the Ohio lottery (such expanding vaccine eligibility to adolescents) throughout the country.

“Our results suggest that state-based lotteries are of limited value in increasing vaccine uptake. Therefore, the resources devoted to vaccine lotteries may be more successfully invested in programs that target underlying reasons for vaccine hesitancy and low vaccine uptake,” said Walkey, a physician at Boston Medical Center.